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Abstract
With randomised trial data confirming that continuous glucose monitoring (CGM) is associated with improvements in
maternal glucose control and neonatal health outcomes, CGM is increasingly used in antenatal care. Across pregnancy, the
ambition is to increase the CGM time in range (TIR), while reducing time above range (TAR), time below range (TBR)
and glycaemic variability measures. Pregnant women with type 1 diabetes currently spend, on average, 50% (12 h), 55%
(13 h) and 60% (14 h) in the target range of 3.5–7.8 mmol/l (63–140 mg/dl) during the first, second and third trimesters,
respectively. Hyperglycaemia, as measured by TAR, reduces from 40% (10 h) to 33% (8 h) during the first to third
trimester. A TIR of >70% (16 h, 48 min) and a TAR of <25% (6 h) is achieved only in the final weeks of pregnancy.
CGM TBR data are particularly sensor dependent, but regardless of the threshold used for individual patients, spending
≥4% of time (1 h) below 3.5 mmol/l or ≥1% of time (15 min) below 3.0 mmol/l is not recommended. While maternal
hyperglycaemia is a well-established risk factor for obstetric and neonatal complications, CGM-based risk factors are
emerging. A 5% lower TIR and 5% higher TAR during the second and third trimesters is associated with increased risk of
large for gestational age infants, neonatal hypoglycaemia and neonatal intensive care unit admissions. For optimal neonatal
outcomes, women and clinicians should aim for a TIR of >70% (16 h, 48 min) and a TAR of <25% (6 h), from as early as
possible during pregnancy.
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Abbreviations
ATTD Advanced Technologies & Treatments for
Diabetes
CE Conformité Européenne
CGM Continuous glucose monitoring
iCGM Intermittently viewed CGM
LGA Large for gestational age
NICU Neonatal intensive care unit
rt-CGM Real-time CGM
TAR Time above range
TBR Time below range
TIR Time in range
In their observational cohort study of 186 pregnancies com-
plicated by type 1 diabetes, Kristensen et al document fetal
exposure to maternal glycaemia using detailed continuous
glucose monitoring (CGM) measures [1]. Combining data
from 92 real-time CGM (rt-CGM) and 94 intermittently
viewed CGM (iCGM) ‘real-world’ users, they measured per-
centage of time spent in, above and below the target glucose
range of 3.5–7.8 mmol/l (63–140 mg/dl), as well as mean
glucose and glycaemic variability metrics throughout preg-
nancy. As expected, maternal glycaemia improved across ges-
tation, with a decrease in mean glucose, HbA1c and glycaemic
variability. The authors confirm that the established clinical
measures, HbA1c and mean glucose, are good markers of the
suboptimal glucose control associatedwith large for gestation-
al age infants and neonatal complications. In addition, they
describe the gestational changes in CGM measures. These
data provide important new insights into the CGM measures
associated with suboptimal maternal glucose control and risk
of neonatal complications. They confirm the need for dynamic
glycaemic metrics beyond HbA1c and will inform the
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development of evidence-based CGM targets in type 1 diabe-
tes pregnancy.
CGM measures across gestation
Across pregnancy, the ambition is to increase the time in range
(TIR) while reducing time above range (TAR), time below
range (TBR) and glycaemic variability. With 84 women using
CGM from before pregnancy, Kristensen et al demonstrate a
substantial 15 percentage point increase in time in range (TIR
3.5–7.8 mmol/l) during the first trimester, rising from 40%
TIR (10 h/day) in the early post-conception period to 55%
TIR (13.2 h/day) by the end of the first trimester. There fol-
lows a striking lack of improvement across the second trimes-
ter, with a 5 percentage point increase bringing the third tri-
mester TIR to 60% (14.4 h/day). This is mirrored by a reduc-
tion in first trimester time above target range (TAR
>7.8 mmol/l), and minimal further reductions in the second
and third trimesters.
Despite differences in patient populations, study design,
statistical analyses, CGM systems and duration of sensor
use, these Swedish CGM profiles are remarkably similar to
those in the multicentre CONCEPTT trial [2]. The
CONCEPTT control group (self-monitoring of blood
glucose) had masked CGMprofiles recorded at approximately
12, 24 and 34 weeks’ gestation, which are indistinguishable
from the first, second and third trimester profiles described by
Kristensen et al. Both report approximately 50% TIR 3.5–
7.8 mmol/l and 40% TAR >7.8 mmol/l in the first trimester,
improving to an average of 60% TIR 3.5–7.8 mmol/l and 33%
TAR >7.8 mmol/l in the third trimester (Table 1). These data
confirm the gap between our expectations of tight glucose
control and the reality of achieving the CGM targets in stan-
dard antenatal care. The 2019 Advanced Technologies &
Treatments for Diabetes (ATTD) consensus recommends tar-
gets for TIR of >70% (16 h, 48 min) and TAR of <25% (6 h),
from as early as possible during pregnancy [3]. In the Swedish
and CONCEPTT studies, women only achieved these targets
towards the end of the third trimester, too late for optimal
neonatal outcomes [1, 2].
CGM measures in relation to HbA1c
The limitations of HbA1c when evaluating individual glucose
control are well recognised [4]. Among women without dia-
betes, HbA1c is lower during pregnancy, as a result of lower
mean glucose [5] and artefactual lowering that is unrelated to
maternal glycaemia [6]. During early pregnancy, artefactual
lowering is attributed to increased erythropoiesis and short-
ened red cell life span [5, 6]. We previously described gesta-
tional reductions of up to 11 mol/mol (1%) HbA1c, without
improvement in self-monitored glucose levels [7]. Women
with higher HbA1c values have the largest HbA1c reductions,
which can be falsely reassuring in those with very poor control
[7].
Astute readers of the paper by Kristensen et al will notice
that maternal HbA1c levels remained unchanged from the sec-
ond to the third trimester despite a 0.3 mmol/l reduction in
mean glucose and a 5% percentage point increase in TIR
(from 55% to 60%). Similar discrepancies between third tri-
mester HbA1c and improving CGM glycaemic measures
(TIR, TAR) were observed in CONCEPTT. Twice as many
CONCEPTT participants achieved target HbA1c compared
with target TIR, suggesting that a TIR of >70% is a more
ambitious goal.
A formula for converting CGM-derived glucose mean glu-
cose into an estimated HbA1c during pregnancy has been pro-
posed [8]. To avoid confusion with laboratory HbA1c assays,
the CGM estimated HbA1c is nowmore appropriately referred
to as a glucose management indicator [9]. Law et al analysed
data from two early randomised trials of intermittent retro-
spective or rt-CGM [10, 11], and these results suggested that,
to minimise fetal overgrowth, clinicians should focus onmean
CGM glucose levels, with a recommended target of 6.4–
6.7 mmol/l (115–120 mg/dl) [12]. Notably, this target was
not achieved, either in the early [10, 11] or in the recent
CGM studies [1, 2] until the final weeks of pregnancy.
CGM measures in relation to fetal
and neonatal outcomes
During organogenesis, the developing fetus is particularly sus-
ceptible to maternal glucose excursions, and peri-conception
hyperglycaemia as measured by HbA1c is strongly associated
with increased risk for major congenital anomaly, stillbirth
and neonatal death [13–16]. Large population-based CGM
studies are required to confirm the associations between
CGM measures and serious adverse pregnancy outcomes.
However, for commonly occurring obstetric and neonatal
complications, including large for gestational age (LGA) in-
fants, neonatal intensive care unit (NICU) admissions and
neonatal hypoglycaemia [13–16], CGM-based risk markers
are emerging.
Kristensen et al found that a 5–7% lower TIR during the
second and third trimesters was associated with increased risk
of LGA and neonatal outcomes, includingmacrosomia, shoul-
der dystocia, neonatal hypoglycaemia or NICU admissions of
>24 h duration. Mothers of infants with vs without LGA had
lower TIR during the second (52% vs 58%) and third trimes-
ters (58% vs 62%). Likewise, mothers of infants with compli-
cations of macrosomia, shoulder dystocia, neonatal
hypoglycaemia or NICU admissions had a 5–6% lower TIR
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(TIR 52% vs 57% and TIR 56% vs 62%) during the second
and third trimesters.
In CONCEPTT, we also found that rt-CGM users
(compared with self-monitoring) achieved a 5–7% higher
TIR in the second and third trimesters, and this was asso-
ciated with a halving in the odds ratio for LGA, neonatal
hypoglycaemia and NICU admissions of >24 h duration
[2]. Taken together, these data indicate that relatively small
(5%) increments in TIR are associated with clinically rel-
evant improvements in neonatal health outcomes.
Importantly, TIR increments are attainable and not
influenced by gestational changes in erythropoiesis, red
cell life span or iron deficiency.
CGM measures in relation to maternal
hypoglycaemia
Outside of pregnancy, percentage of TBR <3.9 mmol/l and
TBR <3.0 mmol/l have both been associated with clinical
episodes of severe hypoglycaemia [17]. During normal
healthy pregnancy, glucose levels are approximately 20%
Table 1 Patterns of glycaemia
among pregnant CGM users with
type 1 diabetes
Glucose measures Kristensen et al, 2019 [1]
iCGM or rt-CGM
N=186a
Feig et al 2017 [2]
rt-CGM
N=108a
CGM target
Laboratory HbA1c, mmol/mol (%)
Trimester 1 52 ± 10.5 (6.9 ± 1.0) 51 ± 7·3 (6·8 ± 0·7)
Trimester 2 45 ± 7.9 (6.3 ± 0.7) 44 ± 6.5 (6.2 ± 0.5)
Trimester 3 46 ± 7.6 (6.3 ± 0.7) 46 ± 6.7 (6·3 ± 0·6)
CGM mean glucose, mmol/l
Trimester 1 7.8 ± 1.4 7·3 ± 1·2
Trimester 2 7.4 ± 1.2 7.6 ± 1.2
Trimester 3 7.1 ± 1.1 6·7 ± 0·9
TIR 3.5–7.8 mmol/lb (%)
Trimester 1 50 ± 14 52 ± 13 >70%
Trimester 2 55 ± 14 53 ± 15 >70%
Trimester 3 60 ± 13 68 ± 13 >70%
TAR >7.8 mmol/lc (%)
Trimester 1 43 ± 15 39 (28–49) <25%
Trimester 2 38 ± 15 43 (29–54) <25%
Trimester 3 34 ± 15 27 (19–37) <25%
TBR <3.5 mmol/ld (%)
Trimester 1 7 ± 5 8 (4–14) <4%
Trimester 2 7 ± 5 3 (1–6) <4%
Trimester 3 6 ± 5 3 (1–6) <4%
Glycaemic variability (% CV)e
Trimester 1 40 ± 7 42 (38–47) <36%
Trimester 2 38 ± 6 35 (31–39) <36%
Trimester 3 36 ± 6 32 (28–37) <36%
a Continuous glucose measures reported were obtained using rt-CGM and iCGM throughout pregnancy by
Kristensen et al and at 10, 24 and 34 weeks in the group using rt-CGM by Feig et al
b TIR refers to % of time spent in range 3.5-7.8 mmol/l (63-140 mg/dl). The TIR target 3.5-7.8 mmol/l (63-
140 mg/dl) proposed by the ATTD consensus group is >70% (16 h 48 min) in type 1 diabetes pregnancy
c TAR refers to % of time spent >7.8 mmol/l (>140 mg/dl). The TAR target >7.8 mmol/l (>140 mg/dl) proposed
by the ATTD consensus group is <25% (6 h) in type 1 diabetes pregnancy. Values are means ± SD or median
(interquartile range) as reported in the publications by Kristensen et al [1] and Feig et al [2]
d TBR refers to the % of time spent <3.5 mmol/l (<70 mg/dl). The TBR target <3.5 mmol/l (<70 mg/dl) proposed
by the ATTD consensus group is <4% (1 h) in type 1 diabetes pregnancy. rt-CGM users spent less time below
3.5 mmol/l compared with iCGM users in the study by Kristensen et al [1]
e Glucose coefficient of variation (CV) thresholds for stable ≤36% and unstable >36% are based on thresholds
outside of pregnancy
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lower [18]. ATBR threshold of less than 3.5 mmol/l, was used
in the Swedish and CONCEPTTstudies [1, 2]. Kristensen et al
demonstrate a substantial (almost twofold) increase in the per-
centage of time spent below 3.5 mmol/l, starting from 6 weeks
and peaking at 12–16 weeks’ gestation. This is consistent with
the well-recognised time-frame associated with maternal risk
of severe hypoglycaemia [19]. As maternal hypoglycaemia is
the rate-limiting factor for achieving tight glycaemic targets in
early pregnancy, these data suggest that the target of
minimising time spent below 3.5 mmol/l to less than 4% (1 h
per day) is most challenging until around 16 weeks’ gestation.
Kristensen et al did not report severe hypoglycaemia
events. In CONCEPTT there were too few severe
hypoglycaemia episodes, (14 with pump, 13 with multiple
daily injection) to examine associations with CGM time be-
low range thresholds. The time spent below 3.5 mmol/l halved
both in insulin pump and multiple daily injection users (from
6% to 3% and from 8% to 4%) from 12 to 34 weeks’ gestation
[20]. Taken together, the Swedish and CONCEPTT data sug-
gest that, with contemporary antenatal care, the proposed
Advanced Technologies & Treatments for Diabetes (ATTD)
consensus recommendation of not more than 4% of time (1 h/
day) spent below 3.5 mmol/l is safely achievable, especially
after 16 weeks. As CGM time below range data are highly
skewed, increasing the lower threshold to 3.9 mmol/l, is asso-
ciated with a substantial two- to threefold increase in time
spent below range. We previously reported up to 15% of time
(3 h 45 min) below 3.9 mmol/l across type 1 diabetes preg-
nancy. Kristensen et al report approximately 10% of time
(2.4 h/day) spent below 3.5 mmol/l in iCGM users. CGM data
on time below range are particularly sensor dependent, but
regardless of the threshold used for individual patients in clin-
ical practice, spending ≥4% of time (1 h/day) below 3.5 mmol/
l or ≥1% of time (15 min/day) below 3.0 mmol/l is not
recommended.
Once maternal insulin sensitivity starts to decline, typically
around 18–20 weeks’ gestation, the challenge is to minimise
postprandial hyperglycaemia [21]. While modern insulin ana-
logues [22, 23], rt-CGM [24] and hybrid closed-loop systems
[25] all contribute to reducing hypoglycaemia in pregnancy,
optimising hyperglycaemia requires early prandial bolus insu-
lin (30–45 min before meals in late gestation) [26] and metic-
ulous attention to dietary intake for meals and snacks [27].
iCGM or rt-CGM?
The factory-calibrated Freestyle Libre iCGM used in the study
by Kerstensen et al [1] is more affordable and free from the
alarms that frustrate rt-CGM users [28]. A study among 74
pregnant women (39 GDM, 24 type 1, 11 type 2 diabetes) led
to a Conformité Européenne (CE) mark meaning that it com-
plies with health, safety and environmental protection
standards. It is the first sensor with a CE mark specifically
for use during pregnancy. The accuracy of the Freestyle
Libre sensor is acceptable and comparable between pregnant
and non-pregnant users [29]. We found similar agreement be-
tween rt-CGM sensor accuracy in early and late gestation and
between pregnant and non-pregnant users [30]. Thus, it is
generally accepted that the sensor accuracy of iCGM and/or
rt-CGM is not affected by gestational physiology.
In the study by Kristensen et al, women with iCGM ap-
peared to spend more time below range at all gestational ages.
Whether this relates to the diabetes self-management behav-
iours of rt-CGM users to prevent and/or avoid hypoglycaemia
or to sensor accuracy of iCGM at lower glucose concentra-
tions is unknown. All CGM sensors are less reliable at glucose
levels below 3.5 mmol/l. However, iCGM users spent strik-
ingly large proportion of time (10%) below target during the
latter part of the first and third trimesters (Fig. 1c in [1]). The
apparently high rates of time below target reported during the
third trimester are unexpected and if women are then snacking
to avoid perceived hypoglycaemia this could potentially un-
dermine efforts to optimise glucose control in late pregnancy.
Despite baseline differences in maternal characteristics
(longer duration of type 1 diabetes, a higher proportion of
insulin pump users among the women using rt-CGM),
Kristensen et al found that rates of LGA and neonatal com-
posite outcome were comparable between iCGM and rt-CGM
users. An adequately powered, large scale, randomised con-
trolled trial would be required to demonstrate that iCGM is
non-inferior to rt-CGM. Meanwhile, the randomised trial ev-
idence supports rt-CGM use for improving neonatal health
outcomes [2].
Clinical CGM targets in pregnant individuals
with type 1 diabetes
The patterns of glycaemia during pregnancy have been stud-
ied for over five decades using laboratory and capillary glu-
cose measures. These informed simple fasting, pre-meal and
post-meal glucose targets in pregnant women with and with-
out diabetes [31]. The patterns of glycaemia using CGM are
more complex and require evidence-based CGM metrics
based on pregnancy outcomes. As noted by Kristensen et al,
day-to-day glucose control was suboptimal despite use of
iCGM or rt-CGM. We still have much to learn on how best
to adjust the timing and dosing of insulin, physical activity and
dietary intake in relation to CGM data. The incorporation of
clinical CGM based-targets may help users and clinicians to
interpret CGM data and to agree specific, measurable and
potentially attainable CGM targets over a typical 2–4 week
antenatal clinic time-frame. Goal setting based onCGM-based
targets could help overcome the current lack of glycaemic
improvement in the second and third trimesters.
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CGM measures give insights into direct fetal exposure to
maternal glycaemia and, unlike HbA1c, are not subject to
changes in gestational physiology. To optimise day-to-day glu-
cose control, women and clinicians should focus their attention
on the dynamic CGM measures of fetal glucose exposure. The
ATTD consensus CGM target recommendations suggest
aiming for a TIR for 3.5–7.8 mmol/l of >70% (16 h, 48 min),
TAR for >7.8 mmol/l of <25% (6 h) and TBR for <3.5 mmol/l
of <4% (1 h) and TBR for <3.0 mmol/l of <1% (15 min) [3].
This ambitious target of >70% TIR is currently only reached
in the final 3–4 weeks of type 1 diabetes pregnancy, which is
too late for optimal neonatal outcomes. In CONCEPTT, only
10% of women achieved a TIR of >70% during the first and
second trimesters, rising to 30% at 34 weeks. Almost twice as
many achieved target HbA1c levels. For optimal obstetric and
neonatal outcomes, women and clinicians should aim to reach a
TIR of >70% (16 h, 48 min) and a TAR of <25% (6 h), from as
early as possible during pregnancy. Women who cannot
achieve the TIR target of >70% in the second and early third
trimester should be encouraged that a 5% increase in TIR is
associated with clinically relevant improvements in neonatal
health.
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